CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Area of Science:

• Oncology
• Nanotechnology
• Biomedical Engineering

Background:

• CXCR4 receptor is overexpressed in triple-negative breast cancer.
• CXCR4 overexpression is linked to tumor growth and metastasis.
• Targeting CXCR4 offers a potential therapeutic strategy for triple-negative breast cancer.

Purpose of the Study:

• To develop novel multicompartmental drug delivery carriers for CXCR4 targeting.
• To immobilize Plerixafor, a CXCR4-binding molecule, onto nanocarriers.
• To evaluate the efficacy of targeted nanocarriers in blocking CXCR4 signaling.

Main Methods:

• Electrohydrodynamic cojetting was used to prepare multicompartmental nanocarriers.
• A novel poly(lactide-co-glycolide) derivative was synthesized for drug immobilization.
• Plerixafor was successfully immobilized onto the nanocarriers.
• Selective uptake and signaling blockade by CXCR4-expressing cells were assessed.

Main Results:

• Successfully prepared multicompartmental drug delivery carriers via electrohydrodynamic cojetting.
• Demonstrated straightforward immobilization of Plerixafor onto a novel PLGA derivative.
• Targeted nanocarriers showed selective uptake by CXCR4-expressing cells.
• Effective blockade of CXCR4 signaling was observed in targeted cells.

Conclusions:

• CXCR4 is a viable target for nanocarrier-based therapies in triple-negative breast cancer.
• The developed nanocarriers demonstrate potential for targeted drug delivery and therapeutic intervention.
• This approach offers a promising strategy to inhibit CXCR4-driven cancer progression.